ascopubs.org

Palbociclib, trastuzumab, pyrotinib and fulvestrant in patients with brain metastasis from ER/PR positive, HER-2 positive breast cancer: Report from an interim analysis of a ...

Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
ascopubs.org

Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.

Risk factors and predictors of tumor recurrence among breast cancer patients in a tertiary government hospital in the Philippines. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global ...
News Medical

Low-dose megestrol strengthens hormone therapy in ER-positive breast cancer

A preoperative trial shows that activating the progesterone receptor with low-dose megestrol can deepen estrogen blockade and curb tumor proliferation, without added toxicity, pointing to a simpler ...
Medscape

Hormonal Treatment for Recurrent ER-Negative, PR-Positive Breast Cancer?

The presence of the progesterone receptor marks this tumor as hormone-responsive and indicates that hormone therapy should be considered as a component of her adjuvant therapy. In some breast cancer ...
Business Wire

Positive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...
MedPage Today

Biomarkers Offer Key Guidance for HR+/HER2- Metastatic Breast Cancer

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...